DrugsControl Media Services

News Detail

US FDA investigates risk of hypocalcemia for patients on dialysis using Prolia (Denosumab) (29-11-2022)

Maryland, 28 Nov 2022: The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis drug Prolia, according to a drug safety communication.


The agency said hospitalizations and death have been reported among ......
View Details

Source : Healio
risk of hypocalcemia Prolia (Denosumab)

Related News